Proteros appoints Dr. Klaus Hinterding as Chief Scientific Officer and member of the management board
Proteros biostructures GmbH announced that Dr. Klaus Hinterding, formerly at Hoffmann-La Roche Ltd., has joined the company as Chief Scientific Officer and member of the management board. Dr. Hinterding brings to Proteros considerable pharmaceutical industry experience that spans early research through to clinical development in various therapeutic areas.
At Novartis, his research contributed to the understanding of the mode-of-action of GilenyaTM, licensed for the treatment of multiple sclerosis, and he led the team that discovered a selective S1P-receptor agonist, currently in Phase II for the same indication. As Life Cycle Leader at Roche he implemented an innovative development and commercial strategy for one of Roche´s leading late-stage development candidates that culminated in a multi-thousand patient clinical program in cardiovascular disease. Dr. Hinterding has led various international research & development collaborations and is an author and inventor of more than 20 patents and publications. He was a post-doctoral fellow at Harvard University and received his PhD in organic Chemistry from the University of Karlsruhe.
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
